Dalian BIO-CHEM Company Limited
603360.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 7.71 | -0.13 | 0.08 | 0.41 |
| FCF Yield | 1.09% | 16.94% | 16.13% | -2.98% |
| EV / EBITDA | 17.11 | 3.44 | 3.59 | 4.84 |
| Quality | ||||
| ROIC | 12.17% | 18.03% | 24.52% | 17.64% |
| Gross Margin | 43.75% | 51.13% | 50.98% | 44.69% |
| Cash Conversion Ratio | 0.45 | 1.19 | 1.19 | 0.57 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.44% | 1.93% | 18.80% | 4.89% |
| Free Cash Flow Growth | -72.68% | -6.74% | 797.02% | -148.89% |
| Safety | ||||
| Net Debt / EBITDA | -0.29 | -0.88 | -0.56 | 0.13 |
| Interest Coverage | 54.75 | 72.59 | 101.62 | 23.92 |
| Efficiency | ||||
| Inventory Turnover | 0.82 | 2.52 | 3.40 | 2.98 |
| Cash Conversion Cycle | 541.65 | 234.82 | 184.22 | 99.68 |